CymaBay Therapeutics
CBAY
$32.48
Share price
0.00%
Change (1 day)
221.27%
Change (1 year)
Categories
CymaBay Therapeutics (CBAY) - Total debt
Total debt on the balance sheet as of December 2023 : $0.11 B
According to CymaBay Therapeutics 's latest financial reports the company's total debt is $0.11 B. A company’s total debt is the sum of all current and non-current debts.
CymaBay Therapeutics - Total debt on balance sheet (from 2013 to 2023)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2023-12-31 | $0.11 B | 25.93% |
| 2022-12-31 | $90.92 M | 76.26% |
| 2021-12-31 | $51.58 M | 2857.68% |
| 2020-12-31 | $1.74 M | -18.88% |
| 2019-12-31 | $2.15 M | |
| 2018-12-31 | $N/A | -100% |
| 2017-12-31 | $6.09 M | -30.69% |
| 2016-12-31 | $8.79 M | -5.48% |
| 2015-12-31 | $9.3 M | 106.52% |
| 2014-12-31 | $4.5 M | 1.39% |
| 2013-12-31 | $4.44 M | -67.64% |
| 2012-12-31 | $13.73 M |
Total debt for similar companies or competitors
| Company | Total debt | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $70.84 B | 61,776.60% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $57.40 B | 50,041.49% | 🇺🇸 USA |
 Xencor XNCR | $83.43 M | -27.13% | 🇺🇸 USA |
 PTC Therapeutics
PTCT | $2.22 B | 1,846.93% | 🇺🇸 USA |